Deferred revenue recognized Deferred Revenue, Revenue Recognized During Period Deferred Revenue, Revenue Recognized During Period Sales Discounts SEC Schedule 12-09, Valuation Allowances and Reserves, Sales Discounts [Member] SEC Schedule 12-09, Valuation Allowances and Reserves, Sales Discounts Supplemental Disclosure of Cash Flow Information: Supplemental Cash Flow Information [Abstract] Income tax expense at Bermuda statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Net Loss Per Common Share Earnings Per Share, Policy [Policy Text Block] Awards vested during period (in shares) Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Statement of Shareholders' Equity [Abstract] Statement of Shareholders' Equity [Abstract] Net loss Net loss Net Income (Loss) Attributable to Parent Richter Richter [Member] Richter Effective Income Tax Rate Reconciliation, Amount Effective Income Tax Rate Reconciliation, Amount [Abstract] Operating lease right-of-use asset Operating Lease, Right-of-Use Asset Additional payment to be received License Agreement, Additional Payment To Be Received License Agreement, Additional Payment To Be Received Accrued compensation-related expenses Employee-related Liabilities, Current Income Statement Location [Axis] Income Statement Location [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-term Debt [Table Text Block] Repayment period upon change in control Debt Instrument, Covenant, Repayment Period Upon Change in Control Debt Instrument, Covenant, Repayment Period Upon Change in Control Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Forfeited (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Revenue from Contract with Customer [Abstract] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Change in Functional Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Capital contribution - other Capital Contribution, Other Capital Contribution, Other Employee Employee [Member] Employee Credits, payments and adjustments Adjustments To Product Revenue Reserves Adjustments To Product Revenue Reserves Other assets Other Assets, Noncurrent Percent of equity awards vested (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Options, Canceled, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Canceled, Number of Shares Brisbane, California Office Space Brisbane, California Office Space [Member] Brisbane, California Office Space [Member] Entity Address, Country Entity Address, Country Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Liabilities Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent [Member] Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Retirement Benefits [Abstract] Net change in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Entity File Number Entity File Number Expected common share price volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Supply Commitment [Line Items] Supply Commitment [Line Items] 2024 Long-Term Debt, Maturity, Year Two Share-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Intrinsic value of options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Currency remeasurement effects on Swiss deferred tax assets Effective Income Tax Rate Reconciliation, Foreign Currency Translation, Amount Effective Income Tax Rate Reconciliation, Foreign Currency Translation, Amount SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Ownership threshold for right of ownership percentage maintenance Related Party Transaction, Ownership Threshold for Right of Ownership Percentage Maintenance Related Party Transaction, Ownership Threshold for Right of Ownership Percentage Maintenance License Agreement, Regulatory Milestones, Upfront Payment Received License Agreement, Regulatory Milestones, Upfront Payment Received License Agreement, Regulatory Milestones, Upfront Payment Received Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Audit Information [Abstract] Audit Information [Abstract] Gross increases — prior period tax positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Variable lease cost Variable Lease, Cost Net deferred tax assets Deferred Tax Assets, Net Weighted average discount rate (as a percent) Operating Lease, Weighted Average Discount Rate, Percent Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Antidilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount R&D expense Research and Development Expense [Member] Sale of Stock [Axis] Sale of Stock [Axis] Liability Class [Axis] Liability Class [Axis] Subsequent Events [Abstract] Subsequent Events [Abstract] Office Space Building [Member] Share of net profits (as a percent) Related Party Transaction, Share Of Net Profits, Percentage Related Party Transaction, Share Of Net Profits, Percentage Deferred tax assets, net of valuation allowance Deferred Tax Assets, Net of Valuation Allowance Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Private Placement Private Placement [Member] Granted (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Total fair value of awards vested in period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Share-based Payment Arrangement, Performance Shares, Activity Share-based Payment Arrangement, Performance Shares, Activity [Table Text Block] Service Agreement Service Agreement [Member] Service Agreement Municipal Bonds Municipal Bonds [Member] Title of Individual [Domain] Title of Individual [Domain] Contract assets Due from Collaborators Due from Collaborators Supply Commitment [Table] Supply Commitment [Table] Options outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Award Type [Domain] Award Type [Domain] Local Phone Number Local Phone Number Assets Assets [Abstract] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Additional Information Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] 2025 Long-Term Debt, Maturity, Year Three Fair Value, Nonrecurring Fair Value, Nonrecurring [Member] Pfizer collaboration revenue Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Options exercisable, Number of Options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Weighted Average Exercise Price (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Other Liabilities Other Liabilities [Member] Options Vested and Expected to Vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract] Non-cash interest expense Interest Expense, Noncash Interest Expense, Noncash Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Accrued interest repayment of debt Repayments of Debt, Accrued Interest Repayments of Debt, Accrued Interest Accrued Expenses and Other Current Liabilities Accrued Expenses and Other Current Liabilities [Member] Accrued Expenses and Other Current Liabilities Concentration risk percentage Concentration Risk, Percentage Property and Equipment, net Property, Plant and Equipment, Policy [Policy Text Block] Notice period for prepayment Debt Instrument, Business Day Notice Period for Prepayment Debt Instrument, Business Day Notice Period for Prepayment Options vested and unvested outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Accumulated Deficit Retained Earnings [Member] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Debt Instrument [Axis] Debt Instrument [Axis] Area leased (in sq ft) Area of Real Estate Property Promotional and Advertising Expense Advertising Cost [Policy Text Block] Proceeds from related party debt financing Proceeds from Related Party Debt Right-of-use assets Deferred Tax Liabilities, Leasing Arrangements Other Liabilities Disclosure [Abstract] Other Liabilities Disclosure [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] (Loss) income before income taxes: Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Collaboration expense to Pfizer Collaboration Expense Collaboration Expense Proceeds from collaborators Additions Proceeds from Collaborators Share-based compensation deferral adjustment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Deferral Adjustment, Amount Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Deferral Adjustment, Amount Related Party [Axis] Related Party [Axis] Deferred revenue, recognition period Deferred Revenue, Recognition Period Deferred Revenue, Recognition Period Accounts receivable Increase (Decrease) in Accounts Receivable Term Loan Secured Debt [Member] Equipment purchases included in accounts payable Capital Expenditures Incurred but Not yet Paid Operating lease right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Maximum aggregate payment from milestones achieved License Agreement, Regulatory Milestones, Maximum, Aggregate Value License Agreement, Regulatory Milestones, Maximum, Aggregate Value Schedule of Deferred Taxes Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Annual vesting percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Ownership percentage Related Party, Ownership Interest Held By Related Party Related Party, Ownership Interest Held By Related Party Deferred revenue Increase (decrease) in deferred revenue Increase (Decrease) in Deferred Revenue Maximum payment from sales-related milestones achieved License Agreement, Sales-Related Milestones, Maximum, Value License Agreement, Sales-Related Milestones, Maximum, Value Available borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Number of operating segments Number of Operating Segments Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Net loss per common share - basic (in dollars per share) Earnings Per Share, Basic Upfront payment received Upfront payment to be received License Agreement, Upfront Payment Received License Agreement, Upfront Payment Received 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Area subleased Lessee, Operating Sublease, Area of Leased Lessee, Operating Sublease, Area of Leased Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] Fair Value, Recurring Basis, Liability [Roll Forward] Fair Value, Recurring Basis, Liability Share-based compensation liabilities Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent Beginning balance (in shares) Ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 2023 Long-Term Debt, Maturity, Year One SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Letter Agreement with Sumitomo Dainippon Pharma, Co., Ltd. Letter Agreement with Sumitomo Dainippon Pharma, Co., Ltd. [Member] Letter Agreement with Sumitomo Dainippon Pharma, Co., Ltd. [Member] Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Cost Cash Advance from Collaboration Partner Collaborative Arrangement, Liability [Roll Forward] Collaborative Arrangement, Liability Expense for matching contribution Defined Contribution Plan, Cost Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Switzerland SWITZERLAND Commercial Paper Commercial Paper [Member] Cash paid for operating lease liabilities Operating Lease, Payments Other Other Noncash Income (Expense) Depreciation Deferred Tax Liabilities, Property, Plant and Equipment Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Ownership threshold for appointment of directors (as a percent) Related Party Transaction, Ownership Threshold for Appointment of Directors Related Party Transaction, Ownership Threshold for Appointment of Directors Maximum payment from regulatory milestones achieved License Agreement, Regulatory Milestones, Maximum, Value License Agreement, Regulatory Milestones, Maximum, Value Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities, Excluding Related Parties Interest Paid, Excluding Capitalized Interest, Operating Activities, Excluding Related Parties Entity Voluntary Filers Entity Voluntary Filers Grant date fair value of options vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Stock options remeasured (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Remeasured During Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Remeasured During Period Upfront payment received Proceeds from Collaborators and License Fees Received Proceeds from Collaborators and License Fees Received Plan Name [Axis] Plan Name [Axis] Maximum payment from milestones achieved License Agreement, Milestones, Maximum, Value License Agreement, Milestones, Maximum, Value Outstanding balance Total Long-term Debt Share-based compensation liabilities Deferred Compensation Share-based Arrangements, Liability, Current Reduced letter of credit if conditions met Lessee, Operating Lease, Restriction or Covenant, Reduced Letter of Credit if Conditions are Met Lessee, Operating Lease, Restriction or Covenant, Reduced Letter of Credit if Conditions are Met Total assets Assets, Fair Value Disclosure Level 1 Fair Value, Inputs, Level 1 [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entity Small Business Entity Small Business Gross increases — current period tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Total liabilities and shareholders’ deficit Liabilities and Equity Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Accrued other expenses Other Accrued Liabilities, Current Long-term debt, less current maturities (related party) Due to Related Parties, Noncurrent Share-based Payment Arrangement, Tranche One Share-based Payment Arrangement, Tranche One [Member] Scenario [Axis] Scenario [Axis] Exercised (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Restricted cash (included in other assets) Restricted Cash Percentage of revenue recognized Collaborative Arrangement, Percentage of Revenue Recognized Collaborative Arrangement, Percentage of Revenue Recognized Additional paid-in capital Additional Paid in Capital Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] MYFEMBREE MYFEMBREE [Member] MYFEMBREE Cost share advance from Pfizer Cost share advance from collaboration partner, current Collaborative Arrangement, Liability, Current Collaborative Arrangement, Liability, Current Liabilities and shareholders’ deficit Liabilities and Equity [Abstract] Richter product supply and royalties Richter Product Supply and Royalties [Member] Richter Product Supply and Royalties Amounts due to collaboration partner, share of profits Accrued Liabilities, Collaboration Agreement, Share of Profits, Current Accrued Liabilities, Collaboration Agreement, Share of Profits, Current SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Entity Interactive Data Current Entity Interactive Data Current Revenue Recognized Upon Completion of Delivery Revenue Recognized Upon Completion of Delivery [Member] Revenue Recognized Upon Completion of Delivery R&D tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Certain Balance Sheet Components Additional Financial Information Disclosure [Text Block] Issuance of shares upon exercise of stock options and release of share awards Stock Issued During Period, Value, Stock Options Exercised Minimum Minimum [Member] Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Marketable securities Marketable Securities, Current 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Total liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure Selling, general and administrative Selling, General and Administrative Expense Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Reclassification Reclassification, Comparability Adjustment [Policy Text Block] Unrecognized tax benefit Beginning of period balance End of period balance Unrecognized Tax Benefits Change in fair value of share-based awards recorded to additional paid-in capital Noncash Increase (Decrease) in Deferred Compensation Share-based Arrangements, Liability Noncash Increase (Decrease) in Deferred Compensation Share-based Arrangements, Liability Subtotal Deferred Tax Assets, Gross Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Sumitovant Other Expenses Agreement Sumitovant Other Expenses Agreement [Member] Sumitovant Other Expenses Agreement Reduction in cost share advance from implied financing costs Collaborative Arrangement, Liability, Costs Recognized as Financing Costs Collaborative Arrangement, Liability, Costs Recognized as Financing Costs United Kingdom UNITED KINGDOM Current liabilities: Liabilities, Current [Abstract] Shares issued Stock Issued During Period, Value, New Issues Operating lease liabilities Increase (Decrease) in Operating Lease Liability Repayment period Collaborative Arrangement, Agreement Costs, Reimbursements Covered by Company, Repayment Period Collaborative Arrangement, Agreement Costs, Reimbursements Covered by Company, Repayment Period Accelerated vesting of awards Share-based Payment Arrangement, Accelerated Cost Extinguishment of Debt Debt Disclosure [Text Block] Options exercisable, Weighted Average Exercise Price (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Schedule of Loss Before Income Taxes and Related Tax Benefit Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Intangibles Deferred Tax Assets, Goodwill and Intangible Assets Line of Credit Line of Credit [Member] Share-Based Compensation Share-based Payment Arrangement [Text Block] Cost share advance from Pfizer, non-current Collaborative Arrangement, Liability, Noncurrent Collaborative Arrangement, Liability, Noncurrent Level 3 Fair Value, Inputs, Level 3 [Member] Leases Lessee, Leases [Policy Text Block] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Unrecognized tax benefit, accrual for interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued ORGOVYX ORGOVYX [Member] ORGOVYX Accounting Policies [Abstract] Accounting Policies [Abstract] Options outstanding, Weighted Average Remaining Contractual Life Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Shares issued (in shares) Stock Issued During Period, Shares, New Issues Number of reporting segments Number of Reportable Segments Accrued professional fees Accrued Professional Fees, Current Present value of future minimum lease payments Operating Lease, Liability Letters of credit Letters of Credit Outstanding, Amount Bermuda Current Federal Tax Expense (Benefit) New Letter Agreement with Sumitomo Dainippon Pharma, Co., Ltd. New Letter Agreement with Sumitomo Dainippon Pharma, Co., Ltd. [Member] New Letter Agreement with Sumitomo Dainippon Pharma, Co., Ltd. Document Transition Report Document Transition Report Foreign currency transaction gain Foreign Currency Transaction Gain (Loss), before Tax Common shares, par value $0.000017727 per share, 564,111,242 shares authorized; 94,858,446 and 91,000,869 issued and outstanding at March 31, 2022 and 2021, respectively Common Stock, Value, Issued Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Summary Of Categories Of Discounts And Allowances Summary Of Categories Of Discounts And Allowances [Table Text Block] Summary Of Categories Of Discounts And Allowances Unrecognized compensation expense, period for recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Beginning balance (in USD per share) Ending balance (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] Officer’s non-deductible share-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Officers, Amount Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Officers, Amount Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Performance stock units (unvested) Performance Shares [Member] Amounts due to Pfizer Increase (Decrease) in Accrued Liabilities, Collaboration Agreement, Current Increase (Decrease) in Accrued Liabilities, Collaboration Agreement, Current Commitments and contingencies (Note 14) Commitments and Contingencies Counterparty Event [Table] Subsequent Event [Table] Leases Lessee, Operating Leases [Text Block] Assets and Liabilities Measured at Fair Value Fair Value, by Balance Sheet Grouping [Table Text Block] Entity Emerging Growth Company Entity Emerging Growth Company Supply Commitment Arrangement [Domain] Supply Commitment Arrangement [Domain] Restricted Stock and Restricted Stock Units Restricted Stock and Restricted Stock Units [Member] Restricted Stock and Restricted Stock Units [Member] Restricted stock awards (unvested) Restricted Stock [Member] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Schedule of Weighted Average Fair Value Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Median Median [Member] Default interest rate (as a percent) Debt Instrument, Default Interest Rate Debt Instrument, Default Interest Rate Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Cowen and Company, LLC Cowen and Company, LLC [Member] Cowen and Company, LLC [Member] Foreign Deferred Foreign Income Tax Expense (Benefit) Share-based compensation liabilities reclassified to equity upon settlement of awards Adjustments to Additional Paid in Capital, Share-based Compensation Liabilities Reclassified to Equity Adjustments to Additional Paid in Capital, Share-based Compensation Liabilities Reclassified to Equity Legal Entity [Axis] Legal Entity [Axis] Auditor Name Auditor Name Cover [Abstract] Cover [Abstract] Amount due from related party Due from Related Parties, Current Restriction period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding, Restriction Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding, Restriction Period Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Revenue from External Customers by Geographic Areas Revenue from External Customers by Geographic Areas [Table Text Block] Marketable Debt Securities Marketable Securities, Policy [Policy Text Block] Royalty expense Royalty Expense Outstanding payment from milestones achieved License Agreement, Milestones, Outstanding, Value License Agreement, Milestones, Outstanding, Value Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Reimbursement of total expenses (as a percent) Collaborative Arrangement, Percentage of Total Allowable Expenses Collaborative Arrangement, Percentage of Total Allowable Expenses Net proceeds from sale of shares Sale of Stock, Consideration Received on Transaction California CALIFORNIA Work in process Inventory, Work in Process, Net of Reserves Vested executive options subject to one-year exercise restriction period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding, Subject to Restriction Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding, Subject to Restriction Period Expenses incurred under agreements Costs and Expenses, Related Party Principal repayment of debt Repayments of Debt, Principal Repayments of Debt, Principal Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Entity [Domain] Entity [Domain] SG&A expense Selling, General and Administrative Expenses [Member] Revenues Revenue from Contract with Customer, Excluding Assessed Tax Income tax receivable Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable Share-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Significant change in unrecognized tax benefits over the next twelve months Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Collaboration expense to Pfizer Collaboration Agreement [Member] Collaboration Agreement Costs covered by company Collaborative Arrangement, Agreement Costs, Reimbursements Covered by Company, Amount Collaborative Arrangement, Agreement Costs, Reimbursements Covered by Company, Amount Share-based compensation deferral adjustment Effetive Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Deferral Adjustment, Percent Effetive Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Deferral Adjustment, Percent Finished goods Inventory, Finished Goods, Net of Reserves Beginning balance Ending balance Fair Value, Recurring Basis, Liability Value Fair Value, Recurring Basis, Liability Value Current taxes: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Stock options Share-based Payment Arrangement, Option [Member] Issuance costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Equity [Abstract] Equity [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Collaboration and License Agreements License Agreement and Collaborative Disclosure [Text Block] License Agreement and Collaborative Disclosure Measurement Input Type [Domain] Measurement Input Type [Domain] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Common Shares Common Stock [Member] Interest income Investment Income, Interest Variable Rate [Axis] Variable Rate [Axis] RYEQO RYEQO [Member] RYEQO Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Liquidity and Capital Resources Liquidity and Capital Resources, Policy [Policy Text Block] Liquidity and Capital Resources, Policy Loss from operations Operating Income (Loss) Operating lease liability Less operating lease liability, current portion Operating Lease, Liability, Current Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Other Other Geographical Area [Member] Other Geographical Area [Member] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Share-based compensation Share-based Payment Arrangement, Noncash Expense Variable Rate [Domain] Variable Rate [Domain] Agreement term Supply Commitment, Initial Agreement Term Supply Commitment, Initial Agreement Term Additional Paid-in Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Depreciation Depreciation Credits and payments made during the current year Credits And Payments Made (Applied) Against Product Revenue Reserves Credits And Payments Made (Applied) Against Product Revenue Reserves Agreement term after first commercial sale Supply Commitment, Agreement Term after First Commercial Sale Supply Commitment, Agreement Term after First Commercial Sale Change in fair value Fair Value, Recurring Basis, Liability, Gain (Loss) Included in Earnings Fair Value, Recurring Basis, Liability, Gain (Loss) Included in Earnings Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Number of securities exercisable by warrant (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Deductions Deferred Revenue, Deductions Deferred Revenue, Deductions Impact of changes in enacted income tax rates Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Other liabilities Increase (Decrease) in Other Operating Liabilities Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Effective Income Tax Rate Reconciliation, Percent Effective Income Tax Rate Reconciliation, Percent [Abstract] Ownership threshold for voting rights (as a percent) Related Party Transaction, Ownership Threshold for Voting Rights Related Party Transaction, Ownership Threshold for Voting Rights Total liabilities Liabilities Raw materials Inventory, Raw Materials, Net of Reserves Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Award Type [Axis] Award Type [Axis] Share-based compensation reclassified to current liabilities Adjustments to Additional Paid in Capital, Share-based Compensation Expense Reclassified to Liabilities Adjustments to Additional Paid in Capital, Share-based Compensation Expense Reclassified to Liabilities Granted (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price End-of-term charge Payment for Debt Extinguishment Cost Payment for Debt Extinguishment Cost Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Stock-based compensation expense Share-based Payment Arrangement, Expensed and Capitalized, Amount Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Measurement Input Type [Axis] Measurement Input Type [Axis] Sunovion Pharmaceuticals, Inc. Sunovion Pharmaceuticals, Inc. [Member] Sunovion Pharmaceuticals, Inc. Total shareholders’ deficit Beginning balance Ending balance Stockholders' Equity Attributable to Parent Net operating losses Operating Loss Carryforwards Common shares issued (in shares) Common Stock, Shares, Issued City Area Code City Area Code Intrinsic value of options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Accrued royalties Accrued Royalties Maturities of marketable securities Proceeds from Maturities, Prepayments and Calls of Marketable Securities Proceeds from Maturities, Prepayments and Calls of Marketable Securities Reimbursement of allowable expenses (as a percent) Collaborative Arrangement, Percentage of Reimbursement of Allowable Expenses Collaborative Arrangement, Percentage of Reimbursement of Allowable Expenses Expected term, in years Measurement Input, Expected Term [Member] Ireland IRELAND Entity Address, City or Town Entity Address, City or Town Loss on extinguishment of debt Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Property and equipment useful life Property, Plant and Equipment, Useful Life Shareholders’ deficit: Stockholders' Equity Attributable to Parent [Abstract] Schedule of Unrecognized Tax Benefits Roll Forward Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Concentrations of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Long-term operating lease liability Operating lease liability, long-term portion Operating Lease, Liability, Noncurrent Measurement Frequency [Domain] Measurement Frequency [Domain] Interest (related party) paid Interest Paid, Excluding Capitalized Interest, Operating Activities, Related Parties Interest Paid, Excluding Capitalized Interest, Operating Activities, Related Parties Total current tax expense Current Income Tax Expense (Benefit) Interest expense Interest Expense Shared costs Deductions Payments for Collaborative Arrangement Payments for Collaborative Arrangement Deferred taxes: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Amounts due to Pfizer Accrued Liabilities, Collaboration Agreement, Current Accrued Liabilities, Collaboration Agreement, Current Defined Contribution Plan Defined Contribution Plan [Text Block] Increase in common shares reserved for grant (in shares) Common Stock, Increase (Decrease) in Capital Shares Reserved for Issuance Common Stock, Increase (Decrease) in Capital Shares Reserved for Issuance Share price (in USD per share) Share Price Accumulated deficit Retained Earnings (Accumulated Deficit) Termination notice term, uncured material breach Supply Commitment, Termination Notice Period, Uncured Material Breach Supply Commitment, Termination Notice Period, Uncured Material Breach Pushdown Accounting Pushdown Accounting [Policy Text Block] Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Restricted stock units and performance stock units (unvested) Restricted Stock Units (RSUs) [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Provision related to sales in the current year Provision To Product Revenue Reserves Relating to Sales Provision To Product Revenue Reserves Relating to Sales Entity Filer Category Entity Filer Category Company match Defined Contribution Plan, Employer Matching Contribution, Percent of Match Expected risk free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share-based Payment Arrangement, Tranche Two Share-based Payment Arrangement, Tranche Two [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Registrant Name Entity Registrant Name Asset Class [Domain] Asset Class [Domain] Revenue Components Revenue From Contract with Customer and Collaborative Arrangements [Text Block] Revenue From Contract with Customer and Collaborative Arrangements Proceeds from stock option exercises Proceeds from Stock Options Exercised Cost share advance from Pfizer Increase (Decrease) in Collaborative Arrangement, Liability Increase (Decrease) in Collaborative Arrangement, Liability Related Party Transaction [Axis] Related Party Transaction [Axis] Total operating costs and expenses Cost of Goods and Services Sold and Operating Expenses Cost of Goods and Services Sold and Operating Expenses Forfeited (in USD per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Income tax expense Total income tax expense Income Tax Expense (Benefit) Other Commitments [Domain] Other Commitments [Domain] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Amendment Flag Amendment Flag 2020 Inducement Equity Award Plan 2020 Inducement Equity Award Plan [Member] 2020 Inducement Equity Award Plan Equity Components [Axis] Equity Components [Axis] Entity Tax Identification Number Entity Tax Identification Number SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Total lease payments Lessee, Operating Lease, Liability, to be Paid Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Accounts Receivable Accounts Receivable [Member] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Sale of Stock [Domain] Sale of Stock [Domain] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Amortization of upfront payment Amortization of Upfront Payment [Member] Amortization of Upfront Payment Inventories Inventories Inventory, Net Valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Share-Based Compensation Share-based Payment Arrangement [Policy Text Block] Bermuda Deferred Federal Income Tax Expense (Benefit) Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Cost share advance Beginning balance Ending balance Collaborative Arrangement, Liability Collaborative Arrangement, Liability Total change in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Product and Service [Axis] Product and Service [Axis] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Entity Public Float Entity Public Float Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Revenues Revenue Benchmark [Member] Weighted-average grant date fair value per share of options granted (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component [Domain] Equity Component [Domain] Short-term lease cost Short-term Lease, Cost Issuance of shares upon release of share awards, net of shares withheld for taxes (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Takeda Commercial Supply Agreement Commercial Manufacturing and Supply Agreement [Member] Commercial Manufacturing and Supply Agreement [Member] Sales of marketable securities Proceeds from Sale of Marketable Securities Proceeds from Sale of Marketable Securities 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Returns SEC Schedule 12-09, Valuation Allowances and Reserves, Returns [Member] SEC Schedule 12-09, Valuation Allowances and Reserves, Returns Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Deferred tax assets: Components of Deferred Tax Assets [Abstract] Vehicles Vehicles [Member] Statement [Line Items] Statement [Line Items] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Remaining transaction price Revenue, Remaining Performance Obligation, Amount Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Issuance of shares upon release of share awards, net of shares withheld for taxes Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Imputed Interest Deferred Revenue, Imputed Interest Deferred Revenue, Imputed Interest Valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Counterparty Name [Domain] Counterparty Name [Domain] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Debt Disclosure [Abstract] Debt Disclosure [Abstract] Share-based compensation awards reclassified to current liabilities Adjustments to Additional Paid in Capital, Change in Fair of Share-based Compensation Expense Recorded to Liabilities Adjustments to Additional Paid in Capital, Change in Fair of Share-based Compensation Expense Recorded to Liabilities Imputed Interest Collaborative Arrangement, Imputed Interest Collaborative Arrangement, Imputed Interest Accrued sales discounts, rebates, and allowances Accrued Sales Discounts, Rebates and Allowances, Current Accrued Sales Discounts, Rebates and Allowances, Current Purchases of marketable securities Payments to Acquire Marketable Securities Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Level 2 Fair Value, Inputs, Level 2 [Member] Capital contribution from former majority shareholder Adjustments to Additional Paid in Capital Related Party Capital Contribution Adjustments to Additional Paid in Capital Related Party Capital Contribution Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] R&D tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Deferred tax assets valuation allowance Valuation allowance Deferred Tax Assets, Valuation Allowance Expected dividend yield Measurement Input, Expected Dividend Rate [Member] Auditor Location Auditor Location Automatic renewal term Supply Commitment, Renewal Term Supply Commitment, Renewal Term Percentage of revenue recognized by counterparty Collaborative Arrangement, Percentage of Revenue Recognized by Counterparty Collaborative Arrangement, Percentage of Revenue Recognized by Counterparty Sunovion Pharmaceuticals Inc. Market Access Services Agreement Sunovion Pharmaceuticals Inc. Market Access Services Agreement [Member] Sunovion Pharmaceuticals Inc. Market Access Services Agreement Number of plans Share-based Compensation Arrangement by Share-based Compensation Payment Award, Number of Plans Share-based Compensation Arrangement by Share-based Compensation Payment Award, Number of Plans Use of Estimates Use of Estimates, Policy [Policy Text Block] Accounts payable Increase (Decrease) in Accounts Payable, Trade Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross U.S. agency securities Agency Securities [Member] Asset Class [Axis] Asset Class [Axis] Document Annual Report Document Annual Report Total other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Forecast Forecast [Member] Vesting [Axis] Vesting [Axis] Deferred revenue, non-current Deferred Revenue, Noncurrent Title of 12(b) Security Title of 12(b) Security Proceeds from issuance of common shares, net of issuance costs paid Proceeds from Issuance of Common Stock Total assets Assets Director Director [Member] Plan Name [Domain] Plan Name [Domain] Deferred tax liabilities: Components of Deferred Tax Liabilities [Abstract] Common shares authorized (in shares) Common Stock, Shares Authorized Geographical [Domain] Geographical [Domain] Reserve -government and other incentives SEC Schedule 12-09, Valuation Allowances and Reserves, Government and Other Incentives [Member] SEC Schedule 12-09, Valuation Allowances and Reserves, Government and Other Incentives Title of Individual [Axis] Title of Individual [Axis] Document Type Document Type Myovant 2016 Equity Incentive Plan 2016 Equity Incentive Plan [Member] 2016 Equity Incentive Plan [Member] Roivant Roivant Sciences, Ltd. [Member] Roivant Sciences, Ltd. [Member] Research and development Research and Development Expense Product and Service [Domain] Product and Service [Domain] Takeda License Agreement Takeda License Agreement [Member] Takeda License Agreement Extension term Lessee, Operating Lease, Renewal Term Interest payable Increase (Decrease) in Interest Payable, Related Party, Net, Current Increase (Decrease) in Interest Payable, Related Party, Net, Current Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Change in unrecognized tax benefits Unrecognized Tax Benefits, Period Increase (Decrease) Termination notice term Supply Commitment, Termination Notice Period Supply Commitment, Termination Notice Period Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Recognition period for remaining transaction price Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Measurement Frequency [Axis] Measurement Frequency [Axis] Net cash (used in) provided by operating activities Net Cash Provided by (Used in) Operating Activities Credit carryforwards Tax Credit Carryforward, Amount Number of classes of stock Common Stock, Number Of Classes Of Stock Common Stock, Number of Classes of Stock Operating Lease Expense Lease, Cost [Table Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Subsequent Event [Line Items] Subsequent Event [Line Items] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Geographical [Axis] Geographical [Axis] Weighted average common share outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Basic Net loss per common share - diluted (in dollars per share) Earnings Per Share, Diluted NovaQuest NovaQuest Securities Purchase Agreement [Member] NovaQuest Securities Purchase Agreement [Member] Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma, Co., Ltd. [Member] Sumitomo Dainippon Pharma, Co., Ltd. [Member] Richter license and milestone revenue License and Service [Member] Amounts due to related parties Due to Related Parties, Current Price of shares (in USD per share) Sale of Stock, Price Per Share Amortization of operating lease right-of-use assets Operating Lease, Right-of-Use Asset, Amortization Expense Vesting [Domain] Vesting [Domain] Product revenue, net Product [Member] Income taxes paid Income Taxes Paid, Net Subsequent Event Subsequent Events [Text Block] Foreign rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Number of shares issued (in shares) Number of shares owned (in shares) Related Party, Ownership Interest Held By Related Party, Shares Related Party, Ownership Interest Held By Related Party, Shares Vesting term Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Chief Financial Officer Chief Financial Officer [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Common shares reserved for grant, annual percentage increase Common Stock, Capital Shares Reserved for Issuance, Annual Percentage Increase as a Percentage of Common Stock Outstanding Common Stock, Capital Shares Reserved for Issuance, Annual Percentage Increase as a Percentage of Common Stock Outstanding Deferred interest payable Increase (Decrease) in Interest Payable, Net, Noncurrent Increase (Decrease) in Interest Payable, Net, Noncurrent Summary of Restricted Share Awards and Restricted Stock Units Activity Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Schedule of Effective Income Tax Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Share-based compensation liabilities, measurement input Deferred Compensation Share-based Arrangements, Liabilities, Current and Noncurrent, Measurement Input Deferred Compensation Share-based Arrangements, Liabilities, Current and Noncurrent, Measurement Input Fair Value Measurements Fair Value Disclosures [Text Block] Accounts payable Accounts Payable, Current Concentration Risk Type [Axis] Concentration Risk Type [Axis] Repricing ratio Share-based Compensation Arrangement by Share-based Payment Award, Options, Repricing Ratio Share-based Compensation Arrangement by Share-based Payment Award, Options, Repricing Ratio Impact of changes in enacted income tax rates Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Accumulated Other Comprehensive (Income) Loss AOCI Attributable to Parent [Member] Inventories Increase (Decrease) in Inventories Accrued royalties payable to Takeda Accrued Royalties, Current Common shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Currency remeasurement effects on Swiss deferred tax assets Effective Income Tax Rate Reconciliation, Foreign Currency Translation, Percent Effective Income Tax Rate Reconciliation, Foreign Currency Translation, Percent Cost of revenue Cost of Goods and Services Sold Chargebacks and administrative fees SEC Schedule 12-09, Valuation Allowances and Reserves, Chargebacks and Administrative Fees [Member] SEC Schedule 12-09, Valuation Allowances and Reserves, Chargebacks and Administrative Fees Document Period End Date Document Period End Date Beginning balance Ending balance Valuation Allowances And Reserves Valuation Allowances And Reserves Stock options repriced Share-based Payment Arrangement, Option, Repriced [Member] Share-based Payment Arrangement, Option, Repriced [Member] Entity Central Index Key Entity Central Index Key Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Deferred product revenue Deferred Net Product Revenue, Current Deferred Net Product Revenue, Current Number of Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Total operating lease cost Lease, Cost Research tax credits Deferred Tax Assets, Tax Credit Carryforwards, Research Facility term Debt Instrument, Term Income Statement Location [Domain] Income Statement Location [Domain] Gross decreases — prior period tax positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Marketable securities Investments, Fair Value Disclosure Supplemental Disclosure of Non-Cash Financing and Investing Information: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Majority Shareholder Majority Shareholder Majority Shareholder [Member] Property and equipment, net Property, Plant and Equipment, Net Agreement term Related Party Transaction, Agreement Term Related Party Transaction, Agreement Term Accrued commercial expenses Accrued Commercial Expenses, Current Accrued Commercial Expenses, Current Other liabilities Other Liabilities, Noncurrent Prepayment penalty Payment for Debt Prepayment Cost Payment for Debt Prepayment Cost Agreement extension term Related Party Transaction, Agreement Extension Term Related Party Transaction, Agreement Extension Term Collaborative Arrangements Collaborative Arrangement, Accounting Policy [Policy Text Block] Reclassification of share-based compensation liabilities to additional paid-in capital upon settlement or maturity of awards Noncash Reclassification of Share-based Compensation Expense from Liabilities to Additional Paid in Capital Noncash Reclassification of Share-based Compensation Expense from Liabilities to Additional Paid in Capital Accrued R&D expenses Accrued Research and Development, Current Accrued Research and Development, Current Amounts due to collaboration partner, reimbursement of allowable expenses Accrued Liabilities, Collaboration Agreement, Reimbursement of Expenses, Current Accrued Liabilities, Collaboration Agreement, Reimbursement of Expenses, Current Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Debt Instrument [Line Items] Debt Instrument [Line Items] Trading Symbol Trading Symbol Restricted stock units and performance stock units (unvested) Restricted Stock Units and Performance Stock Units [Member] Restricted Stock Units and Performance Stock Units Payment of third-party debt financings and redemption and administration fees Repayments of Other Long-term Debt Noncontrolling Interest [Table] Noncontrolling Interest [Table] Foreign currency translation adjustment Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Related Party Transaction [Domain] Related Party Transaction [Domain] Summary of Changes in Fair Value Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis Other assets Increase (Decrease) in Other Operating Assets Total revenues Total revenues Revenues Exercise price of warrants (in USD per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Number of Options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Present value of cost share advance Collaborative Arrangement, Liability, Present Value Collaborative Arrangement, Liability, Present Value Share-based compensation expense from acceleration, modification and subsequent remeasurement of awards Share-based Payment Arrangement, Acceleration, Modification and Remeasurement of Awards Cost Share-based Payment Arrangement, Acceleration, Modification and Remeasurement of Awards Cost Exercise price (in USD per share) Beginning balance (in USD per share) Ending balance (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Warrants Warrant [Member] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Share-based compensation Share-based Payment Arrangement, Expense Cost of Product Revenue Cost of Goods and Service [Policy Text Block] Options exercisable, Weighted Average Remaining Contractual Life Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Deferred Revenue Change in Deferred Revenue [Roll Forward] Change in Deferred Revenue Research and Development Credit Carryforward Research Tax Credit Carryforward [Member] Europe Europe [Member] Entity Current Reporting Status Entity Current Reporting Status Expected risk free interest rate Measurement Input, Risk Free Interest Rate [Member] Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Total income tax expense Effective income tax rate (as a percent) Effective Income Tax Rate Reconciliation, Percent Amortized deferred financing costs Amortization of Debt Issuance Costs Counterparty Name [Axis] Counterparty Name [Axis] Accrued expenses and other current liabilities Accrued expenses and other current liabilities Accrued and Other Liabilities, Current Accrued and Other Liabilities, Current Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Executives, Subject to Exercise Restriction Period Executives, Subject to Exercise Restriction Period [Member] Executives, Subject to Exercise Restriction Period [Member] Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Number of shares issued (in shares) Sale of Stock, Number of Shares Issued in Transaction United States UNITED STATES Common shares par value (in USD per share) Common Stock, Par or Stated Value Per Share Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Current assets: Assets, Current [Abstract] Common shares reserved for grant (in shares) Common Stock, Capital Shares Reserved for Future Issuance Leases [Abstract] Leases [Abstract] Shares remeasured (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Remeasured During Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Remeasured During Period Number of regulatory milestones Collaborative Arrangement, Number of Regulatory Milestones Collaborative Arrangement, Number of Regulatory Milestones Income Taxes Income Tax, Policy [Policy Text Block] LIBOR London Interbank Offered Rate (LIBOR) [Member] Deferred revenue Deferred revenue, current Deferred Revenue, Current Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Entity Address, Postal Zip Code Entity Address, Postal Zip Code Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Issuance of shares upon exercise of stock options (in shares) Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Weighted average common share outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Bermuda Income (Loss) from Continuing Operations before Income Taxes, Domestic Collaboration and License Agreements Schedule of License and Collaborative Agreements [Table Text Block] Schedule of License and Collaborative Agreements Hercules Hercules Loan Agreement [Member] Hercules Loan Agreement [Member] Fair Value, Recurring Fair Value, Recurring [Member] Income Taxes Income Tax Disclosure [Text Block] Settlements Fair Value, Recurring Basis, Liability, Settlements Fair Value, Recurring Basis, Liability, Settlements Cash, cash equivalents and marketable securities Cash, Cash Equivalents, and Short-term Investments Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Related Party [Domain] Related Party [Domain] Country Region Country Region Summary of Stock Option Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Variable interest rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Capital contribution -other Proceeds From Capital Contribution, Other Proceeds From Capital Contribution, Other Shareholders' Deficit Stockholders' Equity Note Disclosure [Text Block] Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Aggregate offering price Sale of Stock, Authorized Amount Sale of Stock, Authorized Amount Pfizer Pfizer [Member] Pfizer Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Auditor Firm ID Auditor Firm ID Additional Brisbane, California Office Space Additional Brisbane, California Office Space [Member] Additional Brisbane, California Office Space Name of Property [Axis] Name of Property [Axis] Deferred employer payroll taxes Social Security Tax, Employer, Deferral, CARES Act Social Security Tax, Employer, Deferral, CARES Act Other comprehensive loss: Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent [Abstract] Entity Address, Address Line One Entity Address, Address Line One Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Entity Address, Address Line Two Entity Address, Address Line Two Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accord Healthcare, Ltd Accord Healthcare, Ltd [Member] Accord Healthcare, Ltd Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Vested (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Entity Shell Company Entity Shell Company Capital contribution from former majority shareholder — share-based compensation Adjustments To Additional Paid In Capital, Capital Contribution From Share-based Compensation Adjustments to Additional Paid in Capital, Capital Contribution from Share-based Compensation Termination notice term, open purchase orders filed Supply Commitment, Termination Notice Period, Open Purchase Orders Filled Supply Commitment, Termination Notice Period, Open Purchase Orders Filled Expected term, in years Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Total current liabilities Liabilities, Current Payment of tax withholding on net settlement of share awards Payment, Tax Withholding, Share-based Payment Arrangement Amount due from related party Increase (Decrease) in Due from Related Parties, Current Regulatory milestone payments received License Agreement, Regulatory Milestones, Payments Received License Agreement, Regulatory Milestones, Payments Received Supply Commitment [Axis] Supply Commitment [Axis] Maximum borrowing commitment Line of Credit Facility, Maximum Borrowing Capacity Money Market Funds Money Market Funds [Member] Reclassification of share-based compensation awards from additional paid-in capital to current liabilities Noncash Reclassification of Share-based Compensation Expense from Additional Paid in Capital to Liabilities Noncash Reclassification of Share-based Compensation Expense from Additional Paid in Capital to Liabilities Maximum percentage of gross pay contribution by company Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Aggregate Intrinsic Value (in thousands) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Current Fiscal Year End Date Current Fiscal Year End Date Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Statement [Table] Statement [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Recently Adopted and Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Other Deferred Tax Assets, Other Schedule of Cash, Cash Equivalents and Restricted Cash Schedule of Cash and Cash Equivalents, Restricted Cash and Cash Equivalents [Table Text Block] Schedule of Cash and Cash Equivalents, Restricted Cash and Cash Equivalents [Table Text Block] Other Commitments [Axis] Other Commitments [Axis] Unrecognized compensation cost Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Lease liability Deferred Tax Assets, Leasing Arrangements Deferred Tax Assets, Leasing Arrangements Amounts due to related parties Increase (Decrease) in Due to Related Parties, Current MSG MSG [Member] MSG Statistical Measurement [Axis] Statistical Measurement [Axis] Amortization of regulatory milestone Amortization of Regulatory Milestone [Member] Amortization of Regulatory Milestone Accounts Receivable, Net Accounts Receivable [Policy Text Block] Schedule of Share-based Compensation Schedule of Share-based Compensation Arrangement, Allocation of Recognized Period Costs [Table Text Block] Schedule of Share-based Compensation Arrangement, Allocation of Recognized Period Costs [Table Text Block] Subsequent Event Subsequent Event [Member] Income tax expense at Bermuda statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Net operating losses Deferred Tax Assets, Operating Loss Carryforwards, Foreign Reclassification from additional paid-in capital Fair Value, Recurring Basis, Liability, Reclassifications Fair Value, Recurring Basis, Liability, Reclassifications Additions Deferred Revenue, Additions1 Deferred Revenue, Additions1 Termination notice period Related Party Transaction, Termination Notice Period Related Party Transaction, Termination Notice Period Beginning balance Ending balance Deferred Revenue Number of independent directors required for audit committee Related Party Transaction, Number of Independent Directors Required for Audit Committee Related Party Transaction, Number of Independent Directors Required for Audit Committee Foreign rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Expected common share price volatility Measurement Input, Price Volatility [Member] Fair Value of Share-based Compensation Liabilities Related to Stock Options Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Total revenue-related reserves SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Name of Property [Domain] Name of Property [Domain] Inventories Inventory, Policy [Policy Text Block] Officer’s non-deductible share-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Officers, Percent Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Officers, Percent Foreign Current Foreign Tax Expense (Benefit) Scenario [Domain] Scenario [Domain] Adjustments to reconcile net loss to net cash (used in) provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Operating lease cost Operating Lease, Cost Additions Deferred Revenue, Additions Related Party Transactions Related Party Transactions Disclosure [Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Public Offering Public Stock Offering [Member] Public Stock Offering [Member] Executive Officer Executive Officer [Member] Maximum percentage of gross pay contribution by employee Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Total deferred tax expense Deferred Income Tax Expense (Benefit) Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Weighted Average Remaining Contractual Life (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term